RU2178307C2 - Производные ов-протеина - Google Patents

Производные ов-протеина Download PDF

Info

Publication number
RU2178307C2
RU2178307C2 RU98113706/14A RU98113706A RU2178307C2 RU 2178307 C2 RU2178307 C2 RU 2178307C2 RU 98113706/14 A RU98113706/14 A RU 98113706/14A RU 98113706 A RU98113706 A RU 98113706A RU 2178307 C2 RU2178307 C2 RU 2178307C2
Authority
RU
Russia
Prior art keywords
protein
immunoglobulin
igg
derivative
native
Prior art date
Application number
RU98113706/14A
Other languages
English (en)
Russian (ru)
Other versions
RU98113706A (ru
Inventor
Совадж Фредерик Дзей Де
Нанси Левин
Ричард Л. ВАНДЛЕН
Original Assignee
Джинентех Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джинентех Инк. filed Critical Джинентех Инк.
Publication of RU98113706A publication Critical patent/RU98113706A/ru
Application granted granted Critical
Publication of RU2178307C2 publication Critical patent/RU2178307C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU98113706/14A 1995-12-27 1996-12-19 Производные ов-протеина RU2178307C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57949495A 1995-12-27 1995-12-27
US08/579494 1995-12-27
US66718496A 1996-06-20 1996-06-20
US08/667184 1996-06-20

Publications (2)

Publication Number Publication Date
RU98113706A RU98113706A (ru) 2000-05-20
RU2178307C2 true RU2178307C2 (ru) 2002-01-20

Family

ID=27077779

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98113706/14A RU2178307C2 (ru) 1995-12-27 1996-12-19 Производные ов-протеина

Country Status (14)

Country Link
EP (1) EP0870026B1 (OSRAM)
JP (1) JP4037905B2 (OSRAM)
CN (1) CN1154726C (OSRAM)
AT (1) ATE267255T1 (OSRAM)
AU (1) AU1520097A (OSRAM)
BR (1) BR9612359A (OSRAM)
CA (1) CA2238307A1 (OSRAM)
CZ (1) CZ9802013A3 (OSRAM)
DE (1) DE69632546T2 (OSRAM)
IL (1) IL124831A0 (OSRAM)
MX (1) MX9804687A (OSRAM)
NZ (1) NZ326592A (OSRAM)
RU (1) RU2178307C2 (OSRAM)
WO (1) WO1997024440A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2341534C2 (ru) * 2004-03-18 2008-12-20 СДж БИОМЕД ИНК. Иммуногенный гибридный полипептид против ожирения и вакцинная композиция на его основе
RU2352583C2 (ru) * 2003-11-13 2009-04-20 Ханми Фарм. Инд. Ко., Лтд. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
DE741187T1 (de) * 1995-05-05 1997-04-30 Hoffmann La Roche Rekombinante Obesitäts-(OB)-Proteine
NZ527007A (en) * 1995-11-22 2005-01-28 Amgen Inc Methods of increasing lean tissue mass using OB protein compositions
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
AU770897B2 (en) * 1996-12-20 2004-03-04 Amgen, Inc. OB fusion protein compositions and methods
ATE351910T1 (de) * 1996-12-20 2007-02-15 Amgen Inc Ob-fusionsprotein enthaltende zusammensetzungen und verfahren
ES2183351T3 (es) * 1997-04-17 2003-03-16 Amgen Inc Composicones que comprenden conjugados de proteina ob humana activa estable con una cadena fc de inmunoglobulinas y metodos.
AU2002300605B8 (en) * 1997-04-17 2006-02-09 Amgen Inc. Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods
US6017876A (en) * 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
PT1037927E (pt) 1997-12-08 2004-10-29 Emd Lexigen Res Ct Corp Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral
US6878811B1 (en) 1998-04-23 2005-04-12 Ajinomoto Co., Inc. Substance with antithrombotic activity and method for detecting glycokallidin
US6492138B1 (en) 1998-05-21 2002-12-10 Amgen Canada Inc. Polynucleotides encoding a novel SHC-binding protein
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
DE60025832T2 (de) 1999-08-09 2006-08-31 Emd Lexigen Research Center Corp., Billerica Mehrere zytokin-antikörper komplexen
AU2154401A (en) 1999-11-12 2001-05-30 Merck Patent Gmbh Erythropoietin forms with improved properties
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
EP1294401B1 (en) 2000-06-29 2007-08-01 EMD Lexigen Research Center Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
ATE359807T1 (de) * 2001-02-21 2007-05-15 Surromed Inc Modifizierte annexin-proteine und verhinderung und behandlung von thrombose
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
DE60239454D1 (de) 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
CA2510180C (en) 2002-12-17 2012-09-11 Merck Patent Gesellschaft Mit Beschraenkter Haftung Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US7314859B2 (en) 2002-12-27 2008-01-01 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
CN100467488C (zh) 2003-12-30 2009-03-11 默克专利有限公司 Il-7融合蛋白
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
WO2005066348A2 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
US7589179B2 (en) 2004-12-09 2009-09-15 Merck Patent Gmbh IL-7 variants with reduced immunogenicity
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US8716220B2 (en) 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
US8642543B2 (en) 2005-09-07 2014-02-04 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
EP1972349A1 (en) * 2007-03-21 2008-09-24 Biocompatibles UK Limited GLP-1 fusion peptides conjugated to polymer(s), their production and use
JP5781501B2 (ja) 2009-04-22 2015-09-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 改変されたＦｃＲｎ結合部位を有する抗体融合タンパク質
CN104147596A (zh) * 2013-05-14 2014-11-19 李荣秀 生物药非共价结合聚合物延长治疗浓度的方法及用途
CN104524568B (zh) * 2015-01-08 2018-04-20 中国人民解放军第二军医大学 一种治疗肥胖症的药物组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
DE741187T1 (de) * 1995-05-05 1997-04-30 Hoffmann La Roche Rekombinante Obesitäts-(OB)-Proteine
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Zhang V. et al. Positional Cloning of the Mouse Obese Gene and its Homan Gomologue. Nature.- V372, 1994, р.425-432. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2352583C2 (ru) * 2003-11-13 2009-04-20 Ханми Фарм. Инд. Ко., Лтд. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ
RU2356909C2 (ru) * 2003-11-13 2009-05-27 Ханми Фарм. Инд. Ко., Лтд. Белковый комплекс, полученный с использованием фрагмента иммуноглобулина, и способ получения такого комплекса
RU2341534C2 (ru) * 2004-03-18 2008-12-20 СДж БИОМЕД ИНК. Иммуногенный гибридный полипептид против ожирения и вакцинная композиция на его основе

Also Published As

Publication number Publication date
AU1520097A (en) 1997-07-28
EP0870026B1 (en) 2004-05-19
CN1205738A (zh) 1999-01-20
JP4037905B2 (ja) 2008-01-23
ATE267255T1 (de) 2004-06-15
IL124831A0 (en) 1999-01-26
DE69632546D1 (de) 2004-06-24
CA2238307A1 (en) 1997-07-10
MX9804687A (es) 1998-10-31
EP0870026A1 (en) 1998-10-14
CN1154726C (zh) 2004-06-23
WO1997024440A1 (en) 1997-07-10
DE69632546T2 (de) 2005-06-30
CZ9802013A3 (cs) 1998-09-16
BR9612359A (pt) 1999-07-13
NZ326592A (en) 2001-05-25
JP2000504210A (ja) 2000-04-11

Similar Documents

Publication Publication Date Title
RU2178307C2 (ru) Производные ов-протеина
US7070959B1 (en) Modified chimeric polypeptides with improved pharmacokinetic properties
EP2507267B1 (en) Compositions and methods for increasing serum half-life of fc fusion proteins
EP1330260B1 (en) Use of il-1 inhibitors and tnf antagonists, partially in combination with recombinant erythropoietins, for the treatment of anemia
US6620413B1 (en) OB protein-polymer chimeras
KR100545720B1 (ko) 당화된 면역글로불린 및 이를 포함하는 면역접합체
US20070100133A1 (en) Erythropoietic compounds
US20050158831A1 (en) Multimeric fusion proteins of TNF superfamily ligands
EP1183353A1 (en) Modified chimeric polypeptides with improved pharmacokinetic properties
JP2012530493A (ja) キメラポリペプチドおよびその使用
US20180280474A1 (en) Treatment of bile acid disorders
JP7173866B2 (ja) コンジュゲートされたｃ１エステラーゼインヒビター及びその使用
US20060205660A1 (en) OB protein-immunoglobulin chimeras
HK1261372A1 (en) Conjugated c1 esterase inhibitor and uses thereof
AU1829101A (en) OB protein derivatives having prolonged half-life